MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
Authors:
Open Access
- 10 September 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients’ samples. The upregulation of miR-33b suppressed proliferation, induced apoptosis, reduced invasion, migration and regulated EMT by an increase of E-cadherin and a decrease of ß-catenin and vimentin. The silencing of EZH2 mimicked the impact of miR-33b overexpression. Furthermore, the inhibition of miR-33b induces cell proliferation, invasion, migration, EMT, and EZH2 expression in non-tumorigenic cells. Importantly, the Kaplan–Meier analysis showed a significant association between high miR-33b expression and better overall survival. These results suggest miR-33b as a suppressive miRNA that could inhibit tumor metastasis and invasion in HER2+ BC partly by impeding EMT through the repression of the MYC–EZH2 loop.Keywords
Funding Information
- Ministerio de Economía, Industria y Competitividad, Gobierno de España (PI18/00006, PI18/00382, Pi18/01219, CB16/12/00241, CB16/12/00481)
This publication has 46 references indexed in Scilit:
- Regulation and Role of EZH2 in CancerCancer Research and Treatment, 2014
- Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expressionEpigenetics, 2014
- Neoadjuvant treatment of breast cancerAnnals of Oncology, 2012
- Mir-33 regulates cell proliferation and cell cycle progressionCell Cycle, 2012
- Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neckAnnals of Oncology, 2011
- miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalingProceedings of the National Academy of Sciences, 2011
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitorsCancer Treatment Reviews, 2009
- MYC stimulates EZH2 expression by repression of its negative regulator miR-26aBlood, 2008
- Carcinoma Invasion and Metastasis: A Role for Epithelial-Mesenchymal Transition?Cancer Research, 2005
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProceedings of the National Academy of Sciences, 2003